日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer.

雄激素受体驱动多胺合成,从而增加患前列腺癌的风险。

Kumar Rajendra, Jonnatan Sheila, Sanin David E, Vakkala Varsha, Kadam Anoushka, Kumar Shivani, Rosen D Marc, Dalrymple Susan L, Zhao Liang, Foley Jackson R, Holbert Cassandra E, Nwafor Ashley, Kittane Srushti, Penner Elizabeth, Apostolova Petya, Warner Samuel, Dang Chi V, Toska Eneda, Thompson Elizabeth A, Isaacs John T, De Marzo Angelo M, Brennen W Nathaniel, Pearce Erika L, Stewart Tracy Murray, Casero Robert A Jr, Denmeade Samuel R, Sena Laura A

The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer.

组蛋白甲基转移酶 KMT2D 是去势抵抗性前列腺癌谱系可塑性和治疗反应的关键介质。

Kittane Srushti, Ladewig Erik, Li Taibo, Love Jillian R, Blawski Ryan, Gao Yangzhenyu, Arruabarrena-Aristorena Amaia, Zhao Peihua, Dalrymple Susan L, Liu Huayang, Guo Xinyu, Sallaku Mirna, Kelkar Nachiket, Garcia-Martinez Liliana, Carmona Sanz Javier, Chen Wanlu, Stoudmann Candice, Baldino Laura, Razavi-Mohseni Milad, Kalemi Ingrid, Beer Michael A, Castel Pau, Brennen W Nathaniel, Scaltriti Maurizio, Morey Lluis, Cocco Emiliano, Ji Hongkai, Chan Ho Man, Battle Alexis, Leslie Christina S, Karthaus Wouter R, Toska Eneda

Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment

达沙替尼可使BRAF/MEK抑制剂在BRAF/MEK抑制剂治疗后病情进展的患者来源的异种移植模型中重新发挥疗效。

Rebecca, Vito W; Xiao, Min; Kossenkov, Andrew; Godok, Tetiana; Brown, Gregory Schuyler; Fingerman, Dylan; Alicea, Gretchen M; Wei, Meihan; Ji, Hongkai; Portuallo, Marie; Bravo, Jeremy; Elad, Vissy; Chen, Yeqing; Toska, Eneda; Fane, Mitchell E; Couts, Kasey L; Villanueva, Jessie; Nathanson, Katherine; Arun, Keerthana M; Warrier, Govind; Yin, Xiangfan; Ding, Jianyi; Liu, Qin; Goyal, Yogesh; Gopal, Y N Vashisht; Davies, Michael A; Herlyn, Meenhard

Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers

抑制NR2F2可恢复内分泌难治性乳腺癌的激素治疗反应

Cai, Yanyan; Zhao, Peihua; Wu, Fan; Zhao, Huiyong; Shao, Hong; Marra, Antonio; Patel, Payal; O'Connell, Elizabeth; Fink, Emma; Miele, Matthew M; Li, Zhuoning; De Stanchina, Elisa; Cocco, Emiliano; Razavi, Pedram; Toska, Eneda; Fanning, Sean W; Xu, Guotai; Sablina, Anna A; Scaltriti, Maurizio; Chandarlapaty, Sarat

Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer

联合抑制KAT6A/B和Menin可逆转乳腺癌中雌激素受体驱动的基因表达程序

Sarah Naomi Olsen,Bryn Anderson,Charlie Hatton,Zhengtao Chu,Christopher Simpkins,Yanhe Wen,Wallace Bourgeois,Elena L Haarer,Myles Brown,Rinath Jeselsohn,Alana L Welm,Eneda Toska,Scott A Armstrong

TFE3 fusion oncoprotein condensates drive transcriptional reprogramming and cancer progression in translocation renal cell carcinoma.

TFE3 融合癌蛋白凝聚体驱动易位性肾细胞癌的转录重编程和癌症进展

So Choon Leng, Lee Ye Jin, Vokshi Bujamin H, Chen Wanlu, Huang Binglin, De Sousa Emily, Gao Yangzhenyu, Portuallo Marie Elena, Begum Sumaiya, Jagirdar Kasturee, Linehan W Marston, Rebecca Vito W, Ji Hongkai, Toska Eneda, Cai Danfeng

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.

不同MET肿瘤改变对I型和II型MET抑制剂的反应性

Murciano-Goroff Yonina R, Foglizzo Valentina, Chang Jason, Rekhtman Natasha, Sisk Ann Elizabeth, Gibson Jamie, Judka Lia, Clemens Kristen, Roa Paola, Ahmed Shaza Sayed, Bremer Nicole V, Binaco Courtney Lynn, Muzungu Sherifah Kemigisha, Rodriguez Estelamari, Merrill Madeline, Sgroe Erica, Repetto Matteo, Stadler Zsofia K, Berger Michael F, Yu Helena A, Toska Eneda, Kannan Srinivasaraghavan, Verma Chandra S, Drilon Alexander, Cocco Emiliano

Retinoblastoma in Albania: A 25-Year Retrospective Analysis

阿尔巴尼亚视网膜母细胞瘤:一项25年回顾性分析

Duka, Enkeleda; Hashorva, Eduart; Kapllanaj, Mirzana; Xhafa, Mirela; Godo, Anila; Tandili, Alketa; Rustemi, Eneda; Petrela, Elizana; Arazi, Mattan; Fabian, Ido Didi; Babameto, Anila; Tabaku, Mirela; Shundi, Lila; Bali, Donjeta

Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer

SMYD2 对染色质修饰因子 KMT2D 的甲基化作用有助于激素依赖性乳腺癌的治疗反应。

Ryan Blawski ,Bujamin H Vokshi ,Xinyu Guo ,Srushti Kittane ,Mirna Sallaku ,Wanlu Chen ,Martina Gjyzari ,Tony Cheung ,Yuhan Zhang ,Christopher Simpkins ,Weiqiang Zhou ,Amanda Kulick ,Peihua Zhao ,Meihan Wei ,Pranavkrishna Shivashankar ,Tatiana Prioleau ,Pedram Razavi ,Richard Koche ,Vito W Rebecca ,Elisa de Stanchina ,Pau Castel ,Ho Man Chan ,Maurizio Scaltriti ,Emiliano Cocco ,Hongkai Ji ,Minkui Luo ,Eneda Toska

ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma

ERK 过度激活是肢端雀斑样黑色素瘤固有和获得性 CDK4/6 抑制剂耐药性的统一逃逸机制。

Kasturee Jagirdar ,Marie E Portuallo ,Meihan Wei ,Matthew Wilhide ,Jeremy A Bravo Narula ,Bailey M Robertson ,Gretchen M Alicea ,Crystal Aguh ,Min Xiao ,Tetiana Godok ,Dylan Fingerman ,Gregory Schuyler Brown ,Meenhard Herlyn ,Vissy M Elad ,Xinyu Guo ,Eneda Toska ,Daniel J Zabransky ,Bradley Wubbenhorst ,Katherine L Nathanson ,Shawn Kwatra ,Yogesh Goyal ,Hongkai Ji ,Qin Liu ,Vito W Rebecca